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Oxytocin secreted by nerve terminals in the posterior pituitary has important actions for ensur-
ing a successful outcome of pregnancy: it stimulates uterine contractions that lead to birth and
it is essential in the milk-ejection reflex, enabling milk to be expelled from the mammary glands
into the mouths of suckling young. Oxytocin also has important actions in the brain: released
from dendrites of neurones that innervate the posterior pituitary, oxytocin auto-excites the neu-
rones to fire action potentials in co-ordinated bursts, causing secretion of pulses of oxytocin.
Central oxytocin actions are blocked by an oxytocin antagonist given into the brain and, conse-
quently, milk transfer stops. Systemic peptide oxytocin antagonist (atosiban) treatment is used
clinically in management of pre-term labour, a major obstetric problem. Hence, it is important
to know whether an oxytocin antagonist given peripherally can enter the brain and interfere
with central oxytocin actions. In the present study, we tested F792, a peptide oxytocin antago-
nist. In urethane-anaesthetised suckled rats, we show that the mammary gland responsiveness
to oxytocin is blocked by i.v. injections of 7 lg/kg of F792, and the milk-ejection reflex is
blocked when F792 is given directly into the brain at a dose of 0.2 lg. To critically test whether
F792 given systemically can enter the brain, we recorded the suckling- and oxytocin-induced
burst-firing of individual antidromically identified oxytocin neurones in the paraventricular
nucleus. Given systemically at 100 lg/kg i.v., F792 acted only peripherally, blocking the milk-
ejecting actions of oxytocin, but not the burst-firing of oxytocin neurones during suckling
(n = 5 neurones in five rats). Hence, this peptide oxytocin antagonist does not enter the brain
from the circulation to interfere with an essential oxytocin function in the brain. Furthermore,
the functions of oxytocin in the brain evidently cannot be explored with a systemic peptide
antagonist.
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The essential role of oxytocin in mammals is in eliciting the transfer
of milk from the alveoli in the mammary glands into the mouths of
the suckled young. The intermittent secretion of large pulses of
oxytocin from the posterior pituitary gland during suckling, or as a
conditioned reflex response to imminent suckling, forms the effer-
ent limb of the milk-ejection reflex (1). Without oxytocin, as in oxy-
tocin-deficient mice, milk cannot be transferred and the young
perish (2,3).
In their landmark studies of the mechanisms of the milk-ejection
reflex, Wakerley and Lincoln (4–6) showed that, in the lactating rat,
oxytocin is secreted in pulses a few minutes apart during suckling,
with each pulse being the result of a high-frequency burst of
action potentials in the magnocellular oxytocin neurones, and
Summerlee and Lincoln (7) showed that the same behaviour occurs
in conscious rats as in anaesthetised rats. Importantly, Wakerley
and Lincoln (4) showed that the bursts were not a response to any
actions of circulating oxytocin, injected in amounts equivalent to
the sharp increases that underlie each milk ejection. Hence, the
electrical and secretory activity of the oxytocin neurones was not
influenced directly by circulating oxytocin. However, to excite the
release of sufficient oxytocin to elicit a milk ejection, many if not
all magnocellular oxytocin neurones must fire a burst of action
potentials within a narrow time window, achieving near synchrony.
Oxytocin neurones in the four magnocellular nuclei indeed show
such co-ordinated burst-firing during suckling (8), oxytocin is
released in the nuclei in response to suckling (9) and centrally
administered oxytocin will dramatically facilitate the milk-ejection
reflex (10), acting both in the magnocellular nuclei (11) and perhaps
at other central sites (12–14). Critically, small amounts of an oxy-
tocin antagonist, given i.c.v. or directly into just one supraoptic
nucleus, completely block the milk-ejection reflex (11); thus, the
source of this oxytocin is likely to be the dendrites of the magno-
cellular oxytocin neurones themselves.
The mechanisms by which such dendritic oxytocin release is
stimulated and then acts to co-ordinate burst-firing is complex,
involving local inhibitory and excitatory interactions in the dendritic
microenvironment (15). These interactions are posited to loosely
couple the magnocellular oxytocin neurones to enable and trigger
co-ordinated burst-firing. The data and inferences from many stud-
ies have been used to develop a computational model that repli-
cates the electrophysiological behaviour of magnocellular oxytocin
neurones during suckling; hence, the assumptions used in this
model about how the identified variables interact are validated (16).
Oxytocin also has an important role in supporting the birth of
young through its powerful uterotonic actions, even if this role
does not appear to be absolutely essential, unlike its importance in
lactation (17). Oxytocin is considered to be more important nor-
mally in further driving established parturition than in its initiation
(18,19), although oxytocin can advance the onset of birth in rats
(20) and oxytocin antagonists can delay it (21). Because threatened
pre-term labour, a major health issue worldwide, may be a result of
the premature secretion of oxytocin, antagonists of oxytocin action
at the oxytocin receptor have been developed for possible use in
the prevention of progression of pre-term labour to pre-term birth.
Presently, atosiban, a peptide antagonist, is in clinical use with
some success (22–24), and nonpeptide antagonists have also been
developed (25,26). In view of the central actions of oxytocin consid-
ered here in parturition and lactation, it is important that these
actions in the brain are not compromised near the end of preg-
nancy by drugs aimed at preventing pre-term birth.
Magnocellular oxytocin neurones also fire in intermittent, intense
bursts in association with the delivery of young (27), and oxytocin
is released within the magnocellular nuclei during birth (28). Impor-
tantly, if the action of oxytocin on magnocellular neurones is
blocked by infusion of an oxytocin antagonist into the supraoptic
nucleus, the local release of oxytocin is reduced and parturition is
prolonged (28), and so the local release of oxytocin is likely to pro-
mote the burst-firing of oxytocin neurones during birth as it does
during suckling.
Oxytocin is released into the brain not only from the axons of
parvocellular neurones, the cell bodies of which are located in the
paraventricular nuclei (29), but also from dendrites of magnocellular
neurones (30,31) and, as shown recently, from centrally projecting
axons of these neurones (32). Such centrally released oxytocin has
central actions that are important for the transition from preg-
nancy to motherhood, underpinning the optimal patterning of oxy-
tocin secretion for birth and milk transfer, and including the
facilitation of maternal behaviour (3,33).
In the present study, we examined whether peripheral adminis-
tration of a peptide oxytocin antagonist (F792, 34,35) can have
actions in the brain. Using the urethane-anaesthetised suckled
milk-ejecting rat model, we tested the hypothesis that this antago-
nist will block the milk-ejection reflex when given directly into the
brain, whereas, if given systemically, it will only act peripherally,
blocking the milk-ejecting actions of oxytocin but not the burst fir-
ing of oxytocin neurones that normally occurs during suckling.
Materials and Methods
Animals
Female Sprague–Dawley rats, weighing 200–250 g and obtained from Bantin
& Kingman (Hull, UK) were housed under a 12 : 12 h light/dark cycle (lights
on 07.00 h) at 20–22 °C with free access to food and water. Mating was
carried out in-house, as required, to generate lactating rats. All procedures
were performed in accordance with UK Home Office regulations governing
animal experimentation with institutional ethical approval. Rats were initially
housed six per cage but were housed individually once mating was con-
firmed by finding a vaginal plug beneath the grid floor of the mating cage.
Intramammary pressure recording
After birth, the rats were kept with their litters (range 8–14 pups,
mean  SEM, 11.5  0.4, n = 13) until days 5–13 of lactation, when all
but one to three pups were removed overnight and kept in a cage with
abundant bedding, prior to the experiment the next morning. Overnight sep-
aration ensures rapid attachment to the nipples, as well as ample milk avail-
ability. For the experiment, the dams were anaesthetised with urethane
(intraperitoneal ethyl carbamate, 1.1 g/kg, 25% w/v solution; Sigma, St
Louis, MO, USA) and the main milk duct of two mammary glands was can-
nulated via the nipple to record intramammary pressure continuously via
pressure transducers (calibrated with a water manometer at 100 and
200 mm water) coupled to a CED 1401 interface and a PC running SPIKE,
version 2 (Cambridge Electronic Design, Cambridge, UK). A jugular vein was
cannulated for injection of oxytocin (10 mU/ml 0.9% saline; Sigma) or F792
(up to 100 lg/ml 0.9% saline; a peptide oxytocin antagonist: dCys-D-Trp-
Ile-allolle-Asn-Carba-6-NmeOrn-NH2, kindly provided by Per Melin (Ferring
Institute, Malm€o, Sweden) (34,35). Intermittent bolus i.v. injections of oxy-
tocin (from 0.5–5 mU) were given to assess mammary gland responsiveness,
and to compare with responses to suckling-induced milk ejections. Mam-
mary gland sensitivity to i.v. oxytocin injection was established initially by
injecting oxytocin in doses from 0.1–2 mU, given > 10 min apart.
Cannulation
A cannula was implanted stereotaxically in all rats for injection of oxytocin or
F792 into a lateral cerebral ventricle. With the rat’s head in a stereotaxic frame,
a hole was drilled into the skull, 1.6 mm lateral and 0.6 mm caudal to bregma,
and a 22-gauge i.c.v. guide cannula (Plastics One; Roanoke, VA, USA) was low-
ered with its tip 3.5 mm below the skull surface, and fixed in place with dental
acrylic and two small screws secured in the skull. Injections [of oxytocin,
1 mU/ll artificial cerebrospinal fluid (aCSF) or F792, 0.05 lg/ll] were given
via a 28-gauge cannula, with its tip 1 mm below the guide cannula tip, con-
nected via polythene tubing to a Hamilton microsyringe.
Suckling-induced oxytocin secretion
The milk-ejection reflex can be observed under urethane anaesthesia (4–6).
Typically, if hungry pups are applied to the nipples 2 h or more after any
surgical interference with the rat, then, after a latent period of 20–40 min,
oxytocin cells begin to display occasional high-frequency bursts of spikes.
© 2015 The Authors. Journal of Neuroendocrinology published by
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These bursts are synchronised amongst the oxytocin cells and so give rise to
the secretion of pulses of oxytocin into the systemic circulation. If suffi-
ciently large, these result in abrupt increases in intramammary pressure of
5–10 mmHg that occur approximately 12 s after the recorded bursts and
are similar to those produced by bolus injections of 0.5–1 mU. The fre-
quency and amplitude of the recorded bursts vary considerably between rats
and between cells within rats, and their magnitude also depends upon the
number of pups suckling and the interval between bursts varies over the
course of an experiment. However, for any given cell, the magnitude and
profile of milk-ejection bursts varies little from one burst to the next. Not
all rats will show an intact reflex but, in many that do not, the reflex can
be initiated by i.c.v. injection of 2 mU of oxytocin. In these experiments, the
suckling stimulus was provided by a litter of eight to 10 pups applied to the
uncannulated nipples, with at least six pups attached throughout.
Electrophysiological recording
Extracellular electrophysiological recordings of the spiking activity of magno-
cellular oxytocin neurones were made from antidromically-identified cells
within the paraventricular nucleus via a dorsal approach (4,5). With the
urethane-anaesthetised rat’s head held in a stereotaxic frame, and the skull
levelled between bregma and lambda, a rectangular hole (approximately
25 mm2) was made with a burr through the skull (rostrally from 0.5 mm cau-
dal, laterally from 1.8 mm lateral to bregma) to allow a glass recording elec-
trode (filled with 0.9% NaCl, tip of approximately 1 lm) to be lowered into the
paraventricular nucleus 7.5 mm below the dorsal surface of the brain. A con-
centric bipolar stimulating electrode (SNEX-100; Clark Electromedical Instru-
ments, Reading, UK) was lowered on to the pituitary stalk through another
hole, made on the midline 1.5 mm rostral to lambda at an angle calculated to
intersect with the pituitary stalk at a depth of 9 mm from the surface of the
brain. Correct positioning of the stimulating electrode tip was assessed by
applying biphasic pulses (0.1–10 mA peak-to-peak at 50 Hz for 2 s) and not-
ing an accompanying increase in intramammary pressure produced as a result
of evoked oxytocin secretion from the posterior pituitary gland.
Magnocellular neurones were identified from the constant latency of anti-
dromic spikes generated by pituitary stalk stimulation. Oxytocin neurones
were distinguished from vasopressin neurones by their intermittent high-
frequency burst discharge during suckling. Discriminated spikes were recorded
using a CED 1401 interface connected to a PC running SPIKE, version 2 (36).
Milk-ejection bursts were recognised as a sequence of > 20 spikes occurring
with unusually short interspike intervals; the first interval of less than 40 ms
in a sequence was taken as the start of each burst for purposes of quantifica-
tion of burst amplitude. The illustrated profiles show instantaneous frequen-
cies: these plot a point at the time of each spike occurrence at a value
proportional to the inverse of the preceding interspike interval (see Results).
Experimental design and analysis
Experiment 1 was designed to test antagonism by F792 of milk-ejecting
actions of exogenous oxytocin, and to determine the dose for maximum
effect. Increasing doses of oxytocin were given as bolus i.v. injections; doses
were 0.5, 1, 1.5 and 2 mU (1 mU = 2.2 ng), which covers the range
secreted per milk ejection during suckling. On the basis that 1 mU of oxy-
tocin generally elicits a near maximal peak intramammary pressure response,
this dose was initially used to test antagonism by F792, given in increasing
i.v. doses from 0.02 lg, at approximately 10-min intervals until effect, which
was taken as complete prolonged suppression of oxytocin effects. Duration
of effect was monitored for up to 2 h in three lactating rats.
Experiment 2 was designed to demonstrate blockade by F792 given by
i.c.v. injection of suckling-induced milk ejections triggered by i.c.v. oxytocin.
Mammary gland sensitivity to 1 mU of oxytocin i.v. was assessed; pups were
put to the nipples and, when at least six were suckling for several minutes,
2 mU of oxytocin was infused via the i.c.v. cannula over 30 s. Following a
series of milk ejections, 0.1 lg of F792 was infused via the i.c.v. cannula; if
milk ejections continued, further i.c.v. F792 injections were given to achieve
the maximum effect of stopping milk ejections. Mammary gland sensitivity
to oxytocin was regularly tested over the following 2 h, and i.c.v. injections
of oxytocin (up to 5 mU) were given to see whether the effects of the
antagonist declined. Five suckled lactating rats were studied.
Experiment 3 tested whether systemically administered F792 inhibits
burst-firing of magnocellular oxytocin neurones in the paraventricular
nucleus induced by suckling and triggered by i.c.v. oxytocin administration.
For this experiment, extracellular recording of an antidromically identified
magnocellular oxytocin neurone was established, and pups were applied to
the nipples, as in Experiment 2. To facilitate suckling-induced burst-firing,
oxytocin (1 mU) was infused via the i.c.v. cannula. Once milk-ejection bursts
of firing were triggered, 100 lg/kg of F792 was injected i.v. (this dose is
> 100-fold greater than the i.c.v. dose that blocked the milk-ejection reflex).
Five lactating rats were used in this experiment, and milk-ejection bursts
before and after i.c.v. F792 were compared within rats.
Results
Experiment 1: Antagonism by F792 of i.v. oxytocin action
on intramammary pressure
Three nonsuckled lactating rats were used to determine a maximally
effective peripheral dose of F792. A cumulative dose of 2.66 lg of
F792 (7.23 lg/kg body weight) abolished any increase in intramam-
mary pressure in response to bolus injections of 1–2.5 mU of oxy-
tocin (i.v., given every 15–20 min) in all three rats for at least
90 min after the last injection of F792 (Fig. 1).
Experiment 2: Interruption of reflex milk-ejections by
central F792 administration
Milk ejections were considered to be established when three or
more successive sharp increases in intramammary pressure were
recorded (Fig. 2) either as a result of just the pups suckling or in
combination with i.c.v. oxytocin administration. Then, F-792 was
administered i.c.v. in experiments on five suckled rats. Three of
these rats exhibited spontaneous milk-ejections and two required
2 mU and 3 mU of i.c.v. oxytocin, respectively, before suckling-
induced increases in intramammary pressure were recorded. In
these experiments, 0.1–3 lg of i.c.v. F792 abolished both sponta-
neous and i.c.v. oxytocin facilitated milk ejections (Fig. 2), beginning
with the highest dose in the first experiment and progressively
lower doses in subsequent experiments. Sequential doses of 2, 3, 4
and then 5 mU of i.c.v. oxytocin (1 mU/ll, aCSF) every 15 min were
ineffective at re-establishing reflex milk-ejection activity for at least
90 min. In all five rats, 1 mU of i.v. oxytocin remained capable of
producing an undiminished increase in intramammary pressure
throughout the experiments (Fig. 2).
Experiment 3: F792 given i.v. and burst-firing of oxytocin
neurones during suckling
In each of five experiments, an antidromically-identified oxytocin
neurone displaying suckling-induced milk-ejection bursts was
© 2015 The Authors. Journal of Neuroendocrinology published by
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recorded before and after i.v. injection of 100 lg of F792. In all five
experiments, i.v. F792 had no effect on the bursting activity of
these neurones, despite producing a complete and long lasting
block of mammary gland responses in response to i.v. oxytocin
(measured in three of the five experiments). In one of these experi-
ments, i.c.v. injection of 2 mU of oxytocin before administration of
the antagonist evoked five bursts containing 78  3 spikes
(mean  SEM) within 2.5 s. At 25 min after injection of F792, a
second i.c.v. injection of 2 mU of oxytocin evoked four bursts con-
taining 79  3 spikes within 2.5 s; no other bursts were observed
in this experiment. In a second experiment (Fig. 3), three bursts
were observed before administering F792, with 28, 32 and 32
spikes, respectively, within 2 s. After i.v. injection of F792, two fur-
ther bursts were observed with 41 and 43 spikes within 2 s. Injec-
tion of 2 mU of oxytocin i.c.v. produced the expected facilitation of
burst amplitude and frequency, eliciting five bursts with between
74 and 84 spikes within 2 s (mean 78  1 spikes), followed by two
later bursts (76 and 77 spikes within 2 s). In the other three experi-
ments, as in the first two experiments, bursts that followed i.v.
injection of F792 were indistinguishable from those observed before
injection. Figure 3 shows the profile, for each of these experiments,
of the last burst observed before injection of F792, with the first
burst observed after.
Discussion
The first experiment reported in the present study provided evi-
dence for the effectiveness of F792 as a peptide antagonist of oxy-
tocin action with respect to its essential role in effecting ejection
of milk in lactation. A cumulative i.v. dose of 7.2 lg/kg body weight
was effective against bolus i.v. injections of oxytocin in the physio-
logical range [i.e. as secreted during sucking (4–6) for at least
90 min]. The second experiment tested whether any entry of F792
into the brain would interfere with the milk-ejection reflex in
anaesthetised lactating rats. This showed that i.c.v. injection of the
antagonist abolished suckling-induced milk ejections, as registered
by cessation of sharp brief increases in intramammary pressure,
whether or not i.c.v. injection of oxytocin was given to activate the
milk-ejection reflex. The lowest dose of i.c.v. F792 given (0.1 lg)
inhibited milk ejections for 90 min from injection, and this inhibi-
tion was not overcome by repeated i.c.v. oxytocin injections, even
at cumulative oxytocin doses six-fold greater than were effective in
evoking milk ejections before the i.c.v. F792 infusion. There was an
eventual return during continuous suckling of intermittent increases
in intramammary pressure, although of much reduced amplitude,
without a reduction in mammary gland responses to bolus i.v. oxy-
tocin injections. This resumption of milk ejections indicates
reversibility, which may reflect clearance of F792 from the brain.
Hence, we infer that, given i.c.v., F792 antagonises the actions
resulting from oxytocin released in the brain that are essential for
the milk-ejection reflex. From previous studies, it is likely that, simi-
lar to other oxytocin antagonists, F792 blocks the priming and
auto-excitation of burst-firing of oxytocin neurones during suckling
that is dependent on the somato-dendritic release of oxytocin by
the magnocellular oxytocin neurones themselves (11,16). Further
evidence for the importance of local oxytocin in auto-excitation
during suckling is that local inhibition of leucine aminopeptidase,
which is released by oxytocin neurones and inactivates extracellular
oxytocin, has effects similar to i.c.v. oxytocin with respect to pro-
moting burst-firing (37).
On this background, the third experiment was designed to criti-
cally test whether F792 could enter the brain from the circulation
when present at peripheral levels supramaximal for blocking oxy-
tocin actions on the mammary gland. We found that, in this state,
1 mU i.v. 1 mU i.v.
1 mU i.v.
F792 i.v.
0.02 µg
F792 i.v.
0.04 µg
F792 i.v.
0.2 µg
F792 i.v.
0.4 µg
F792 i.v.
2 µg
1 mU i.v. 1.5 mU i.v. 2 mU i.v.
10 mmHg
10 min
Fig. 1. Determination of the i.v. dose of F792 (OTA) that blocks the milk-ejecting action of oxytocin (OT). Intramammary pressure recording in urethane-
anaesthetised lactating rats (day 9); rats were not suckled. Bolus i.v. doses of 0.5, 1.0, 1.5, 2 mU of oxytocin (1 mU = 2.2 ng) were given at approximately
10-min intervals. F792 was given after bolus injections of 1 mU of oxytocin in increasing doses (as shown) until there was no detectable response to
subsequent oxytocin injections. Oxytocin action was blocked for > 80 min after injection of the 2-lg dose (cumulative 2.66 lg) of F792.
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suckling-stimulated burst-firing of magnocellular oxytocin neurones
in the paraventricular nucleus continued undiminished, with the
complete absence of mammary gland milk-ejection responses after
each burst and after i.v. injection of test doses of oxytocin. More-
over, i.c.v. injections of oxytocin still evoked increased background
firing activity and burst-firing of the oxytocin neurones (Fig. 3),
indicating intact auto-excitatory oxytocin actions in the face of
highly effective peripheral F792 levels.
Hence, we conclude that the peptide oxytocin antagonist F792
does not enter the brain to interfere with the actions of oxytocin
released in the brain, at peripheral concentrations that strongly
suppress peripheral oxytocin actions: including the actions of oxy-
tocin that is presumably still secreted from the posterior pituitary
in pulses following the continuing burst-firing of oxytocin neurones
during suckling. Notably, this continued burst-firing of oxytocin
neurones during suckling with peripheral actions of oxytocin
blocked by F792 reinforces the long-standing inference that the
effectiveness of the suckling stimulus in evoking burst-firing is a
result of the sensory neural input activated by suckling and not a
consequence of a systemic action of oxytocin. For example,
Wakerley and Lincoln (4) found that i.v. injections of oxytocin did not
influence ongoing burst-firing of oxytocin neurones during suckling.
A different prediction follows from the present study with regard
to the secretion and action of oxytocin in parturition. F792 has a
significantly improved potency, duration of action and bioavailabil-
ity (34,35) compared to atosiban, which has had limited success in
1 mU i.v.
2 mU i.c.v. 3 mU i.c.v.
4 mU i.c.v. 5 mU i.c.v. 5 mU i.c.v.
1 mU i.v. 1 mU i.v.
1 mU i.v.1 mU i.v.
5 mU i.c.v.
1 mU i.v.
10 mmHg
Intramammary 
pressure
2 mU i.c.v.
m m m m
m m m m
m m m m
0.1µg F792 i.c.v.
0.1µg F792 i.c.v.
m mm
m
10 min
Fig. 2. Intramammary pressure recording in a urethane- anaesthetised lactating rat (day 11/12, litter of 10 pups) at least six pups suckling throughout: the
trace is a continuous recording. A bolus i.v. dose of 1 mU oxytocin demonstrated mammary gland sensitivity to oxytocin, and, in response to the suckling
stimulus, reflex milk ejections (m) were observed. Oxytocin (2 mU) given i.c.v. triggered a sequence of 8 large milk ejections a few minutes apart. After an i.c.v.
infusion of 0.1 lg F792 three further milk ejections were seen, but after a second i.c.v. infusion of 0.1 lg F792 no further spontaneous milk ejections were
observed, even after i.c.v. infusions of 2, 3, 4, and 5 mU oxytocin. Bolus i.v. doses of 1 mU oxytocin elicited sharp increases in intramammary pressure similar
to the initial response, showing intact sensitivity of the mammary gland to oxytocin. About 90 min after the second injection of F792 one small spontaneous
milk ejection (m) was observed.
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delaying pre-term birth in women experiencing pre-term labour
(23–26). As indicated above, there is substantial evidence available
from human and animal studies indicating an important role in
parturition of oxytocin, including its secretion in a pulsatile manner
(2,19). Similar to the pulsatile secretion of oxytocin in response to
suckling in lactation, pulsatile oxytocin secretion during birth has
been recorded in rats, and was shown to be a consequence of burst
firing of magnocellular oxytocin neurones (27), and this evidently
involves local auto-excitatory oxytocin actions because birth is slo-
wed by an oxytocin antagonist given into the magnocellular nuclei
(28). However, this activity of the neurones and the subsequent
secretion of an oxytocin pulse is associated with a birth, indicating
that, during parturition, oxytocin neurones are stimulated by posi-
tive-feedback neural signals from the birth canal, which is dis-
tended as a foetus is born (38). Hence, if births are interrupted by
the action of an oxytocin antagonist on the myometrium, the posi-
tive-feedback signal will be lost and oxytocin neurone activity will
subside. It follows that, in contrast to the expected continuation of
secretion of oxytocin pulses during suckling in lactation with block-
ade of peripheral actions by an oxytocin antagonist, in late preg-
nancy (e.g. pre-term labour), the antagonist will effectively, but
indirectly, inhibit oxytocin secretion and conserve the posterior
pituitary store of oxytocin. This remains to be tested.
The key conclusion from the present study is that F792, when
given peripherally in a dose supramaximal for blocking peripheral
oxytocin actions, does not enter the brain. Consequently, oxytocin-
dependent processes in the brain in late pregnancy, when a peptide
oxytocin antagonist is likely to be used clinically, are unlikely to be
affected by peripheral antagonist administration. This should be a
primary concern in the design and testing of any oxytocin antago-
nist, regardless of whether it comprises a peptide or especially a
nonpeptide that is more likely to be able to enter the brain (39).
There are several actions of oxytocin within the brain in pregnancy
and postpartum that are important for a successful outcome of
pregnancy. These include an important role for oxytocin released in
late pregnancy within the magnocellular nuclei with respect to
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Fig. 3. Demonstration that systemically administered F792 does not interfere with the excitation of magnocellular paraventricular nucleus oxytocin neurones
during suckling. (A) Instantaneous firing rate record of a single antidromically identified paraventricular nucleus oxytocin neurone in a urethane-anaesthetised
lactating rat with at least six pups suckling throughout. b1, b2 and b3 indicate three spontaneous milk-ejection bursts, after which 100 lg of F792 was
injected i.v., as shown by the orange arrow. b4 and b5 mark two subsequent milk-ejection bursts, after which 2 mU of oxytocin was injected i.c.v., producing
the expected facilitation of burst amplitude and frequency. The profiles of the two bursts before injection of F792 and the two bursts after are expanded
below. (B) Comparison of milk-ejection burst profiles before and after i.v. injection of 100 lg of F792. Blue dots are from the last spontaneous milk ejection
before injection of F792, and the orange dots are from the first burst after that injection. The total number of spikes within 2 s from the start of the burst is
indicated, as is the time elapsed after injection of F792. The three cells (in three different rats) displayed bursts of differing magnitudes and amplitudes but, in
each case, the burst amplitude and profile was completely unaffected by F792 injection.
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inducing, along with the actions of oestrogen, changes in oxytocin
neurone electrical properties and the local circuitry regulating oxy-
tocin neurones, which are both important for their co-ordinated
burst-firing during parturition and lactation (2,40). Clearly, an oxy-
tocin antagonist that enters the brain may interfere adversely with
these preparations and impair pulsatile oxytocin secretion in partu-
rition and milk transfer to the newborn. Oxytocin released in the
brain during birth has important actions for ensuring the rapid
expression of maternal behaviour after birth (3,33). Furthermore,
oxytocin in the brain has more general actions in facilitating social
affiliation (3,41,42) and any negative action of an oxytocin antago-
nist on this process, especially around birth, would clearly be an
unwanted side-effect.
Investigations of the multiple roles in behaviours and abnormal
mental states that have been postulated for oxytocin have gained
popularity recently. Many of these studies have involved insufflat-
ing large doses of oxytocin intranasally, in the expectation that the
peptide will reach the brain, by an undefined direct route (43–45).
There are transport mechanisms for some peptides that enable
transport across the blood–brain barrier (46), although none has
been identified for oxytocin, and an action of oxytocin at circum-
ventricular organs has not been described. Even after raising circu-
lating concentrations of oxytocin massively, the integrity of the
blood–brain barrier is intact (47) and there is negligible transfer
from blood to CSF (48,49) (at least under normal conditions). It is,
however, possible that oxytocin given intranasally (or by any other
systemic route) will have peripheral actions, leading indirectly to
central effects (45). To exclude such peripheral actions, it would be
appropriate to make use of an oxytocin antagonist that potently
blocks peripheral actions but which does not enter the brain in
studies with intranasal oxytocin.
In principle, an appropriate way of investigating the actions of
oxytocin in the brain, apart from the use of genetically modified
animals, would be to study the effects of an oxytocin antagonist.
Many peptide oxytocin antagonists have been synthesised (25,26)
and, as in the present study, were shown to be active in vivo,
including in the brain in animal models (50), and against peripheral
oxytocin actions. To our knowledge, none of these peptide antago-
nists have been shown to enter the brain, and so they are not use-
able for studies of oxytocin actions in the brain in humans. From
the present study, F792 also is not suitable for exploring oxytocin
actions in the brain in humans: indeed, should peripheral adminis-
tration of this peptide antagonist, with or without prior oxytocin
administration, produce effects on brain function, these are
expected to be a result of antagonism of peripheral, not central,
actions of oxytocin. Hence, the present study demonstrates that
F792 has properties appropriate for use as a selective antagonist of
peripheral oxytocin actions without entering the brain and compro-
mising the activity of oxytocin systems therein.
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